Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611533 · ClinicalTrials.gov registry record · NA
Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women
A NA study of Menopause and Cognitive Disturbances, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00611533: Completed NA study of Menopause and Cognitive Disturbances, sponsored by University of Pennsylvania.
NCT00611533 is a NA study of Menopause and Cognitive Disturbances that has completed, run by University of Pennsylvania. The registered enrollment target is 16 participants, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00611533, a NA study of Menopause and Cognitive Disturbances, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the efficacy of atomoxetine (ATX) treatment for the mild to moderate cognitive disturbances frequently experienced by women during the menopause transition. In addition, we seek to determine, using the Brown Attention Deficit Disorder Scale (BADDS), whether and to what degree peri- and early post-menopausal women experience cognitive disturbances which overlap with the impairments of executive function characteristic of adults with attention deficit disorder (ADHD).
Primary Outcome
Raw scores for 5 clusters (organizing/activating, attention/concentration, alertness/effort/processing, managing affect interference, and working memory/recall) on the BADDS were converted to T scores which range from 50-99, with higher scores meaning greater impairment.
Conditions Studied
Interventions
- DRUG placebo
- DRUG atomoxetine
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-04 |
| Phase | NA |
What the finished NCT00611533 record still lists
NCT00611533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00611533 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00611533 about?
NCT00611533 is a clinical study titled "Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women". The purpose of this study is to examine the efficacy of atomoxetine (ATX) treatment for the mild to moderate cognitive disturbances frequently experienced by women during the menopause transition. In addition, we seek to determine, using the Brown Attention Deficit Disorder Scale (BADDS), whether an...
What is the current status of trial NCT00611533?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2004-05. Estimated completion is 2008-04.
What conditions does trial NCT00611533 study?
This clinical trial studies the following conditions: Menopause, Cognitive Disturbances.
What interventions are being tested in trial NCT00611533?
The interventions under investigation include: placebo (DRUG), atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00611533?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00611533 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00611533's enrollment target sits among peer trials
16 54th of 54 higher than 1 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hot Flashes and Neurovascular Function in Women
RECRUITING · NA
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
-
Improving Sympathetic Activity, Hot Flashes, and Sleep in Midlife Women Using Inspiratory Muscle Strength Training
RECRUITING · NA
-
Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females
RECRUITING · NA
-
Depression, Aging, Stress and Heart Health Study
RECRUITING · NA
-
Choline Dose Ranging in Postmenopausal Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia